News

PharmiWeb

EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes

HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of ...
BioWorld

Nephrodi Therapeutics signs collaboration agreement for kidney-targeted AMPK activator NDI-5001

Nephrodi Therapeutics Inc. has entered an agreement with The McQuade Center for Strategic Research and Development LLC (MSRD), a member of the Otsuka family of pharmaceutical companies, to collaborate ...
BioWorld

Biolexis Therapeutics’ AMPK activator shows preclinical efficacy in obesity, type 2 diabetes

Biolexis Therapeutics Inc. is working on developing orally available, small-molecule AMPK activators that have been found to stimulate AMPK activity as well as dose-dependently enhance glucose uptake ...
Business Insider

Betagenon/Baltic Bio Announces Positive Results From a 28-day Phase IIa Trial of the First-in-class AMPK Activator O304 in Type 2 Diabetics

STOCKHOLM, Nov. 2, 2017 /PRNewswire/ -- O304 reduces significantly fasting plasma glucose (FPG) in type 2 diabetics The main study results are not yet finalized. Review of the initial data showed that ...
JSTOR Daily

The AMPK-PP2A axis in insect fat body is activated by 20-hydroxyecdysone to antagonize insulin/IGF signaling and restrict growth rate

Dongwei Yuan, Shun Zhou, Suning Liu, Kang Li, Haigang Zhao, Shihui Long, Hanhan Liu, Yongfang Xie, Yunlin Su, Fengwei Yu, Sheng Li Proceedings of the National Academy of Sciences of the United States ...
Business Wire

Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)

LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic ...
Business Wire

Nimbus Therapeutics Achieves Research Milestone in Collaboration with Lilly

BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful ...